[en] Prostate cancer in men has now surpassed lung cancer as the most frequent non-cutaneous cancer. From a biological perspective, prostate carcinoma is unique among human malignancies in the wide discrepancy that exists between the prevalence of 'latent' cancer, recognizable only histologically, and that of the clinical disease. Histologically detected localized prostate cancers are heterogeneous, with only a small subset having undergone all of the malignant changes required to produce clinically aggressive tumors. Most of these 'latent' carcinoma never become fully malignant and do not threaten the life or well-being of the host. At present, it is not possible to predict which localized cancers will progress to clinically overt disease. Likewise, many patients have underevaluated and unpredictable extent of their prostate carcinoma, thus resulting in inadequate therapeutic strategies. It is clear that we need to identify molecular and/or cellular markers that are able to define the invasive and metastatic potential of prostate cancer on an individual patient basis. Acquisition of metastatic ability is a definitive criterion by which substage localized prostate cancers. Under the light of recent studies designed to identify some of the features associated with the metastatic phenotype of prostate cancer, the authors review recent advances aimed at gaining insight into those factors that may be involved in prostate cancer metastasis.
Disciplines :
Urology & nephrology
Author, co-author :
Waltregny, David ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Labo de recherche sur les métastases
Castronovo, Vincenzo ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie générale et cellulaire
Albelda S.M., Buck C.A.: Integrins and other cell adhesion molecules. FASEB J., 4: 2868-2880, 1990.
American Cancer Society: Cancer facts and figures, 1990.
Arason A., Barkardottir R.B., Egilsson V.: Linkage analysis of chromosome 17q markers and breast-ovarian cancer in Icelandic families, and possible relationship to prostate cancer. Am. J. Hum. Genet., 52: 711-717, 1993.
Austenfiel M.S., Davis B.E.: New concepts in the treatment of stage D1 adenocarcinoma of the prostate. Urol. Clin. North Am., 17: 867-884, 1990.
Backer J.M., Mendola C.E., Kovesdi I., Fairhurst J.L., Ohara B., Eddy R.L., Shows T.B., Mathews S., Murthy V.V., Chagarti R.S.: Chromosomal localization and nucleoside diphosphate kinase acitivity of human metastasis-suppressor genes nm23-1 and nm23-2. Oncogene, 8: 497-502, 1993.
Batson O.V.: The function of the vertebral veins and their role in the spread of metastases. Ann. Surg., 112: 138-149, 1940.
Bergerheim U.S., Kunimi K., Collins V.P., Ekman P.: Deletion mapping of chromosomes 8, 10 and 16 in human prostatic carcinoma. Genes Chromosom. Cancer, 3: 215-220, 1991.
Berrettoni B.A., Carter J.R.: Mechanisms of cancer metastasis to bone. J. Bone Jt. Surg. Am., Vol. 68A: 308-312, 1986.
Bevilacqua G., Sobel M.E., Liotta L.A., Steeg P.S.: Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential. Cancer Res., 49: 5185-5190, 1989.
Boring C.C., Squires T.S., Tong T.: Cancers statistics. Cancer J. Clin., 41: 1, 1991.
Boucheix C., Benoit P., Frachet P., Billard M., Worthington R.E., Gagnon J., Uzan G.: Molecular cloning of the CD9 antigen. A new family of cell surface proteins. J. Biol. Chem., 266: 117-122, 1991.
Brawer M.K., Lange P.H.: Prostate-specific antigen: its role in early detection, staging, and monitoring patients with prostatic carcinoma. J. Endourol., 3: 227-236, 1989.
Bussemakers M.G., van Moorselaar R.J.A., Giroldi L.A., Ichikawa T., Isaacs J.T., Takeichi M., Debruyne F.M.J., Schalken J.A.: Decreased expression of E-cadherin in the progression of rat prostatic carcinoma. Cancer Res., 52: 2916-2922, 1992.
Carpenter G.: Receptors for epidermal growth factor and other polypeptide mitogens. Ann. Rev. Biochem., 56: 881-814, 1987.
Carter B.S., Beaty T.H., Steinberg G.D., Child B., Walsh P.C.: Mendelian inheritance of familial prostate cancer. Proc. Natl. Acad. Sci. USA, 89: 3367-3371, 1992.
Carter H.B., Coffey D.S.: Prostate cancer: the magnitude of the problem in the United States. In: A multidisciplinary analysis of controversies in the management of prostate cancer, Coffey D.S., Resnick M.I., Dorr F.A., Karr J.P. (Eds.), pp. 1-9. Plenum Press, New York, 1988.
Carter H.B., Coffey D.S.: The prostate: an increasing medical problem. Prostate, 16: 39-48, 1990.
Carter B.S., Ewing C.M., Ward W.S., Treiger B.F., Aalders T.W., Schalken J.A., Epstein J.I., Isaacs W.B.: Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc. Natl. Acad. Sci. USA, 87: 8751-8755, 1991.
Carter H.B., Piantadosi S., Isaacs J.T.: Clinical evidence for and implications of the multistep development of prostate cancer. J. Urol., 143: 742-746, 1990.
Castronovo V.: Laminin receptors and laminin-binding proteins during tumor invasion and metastasis. Invasion and Metastasis, 13:1-30, 1993.
Catalona W.J.: Prostate cancer. New York, NY, Grune & Stratton, 1984.
Catalona W.J., Ratliff T.L., Yuan J.J.: Serum prostate specific antigen as a first-line screening test for prostate cancer. J. Urol., 143: 313A, 1990.
Catalona W.J., Smith D.S., Ratliff T.L., Dodds K.M., Coplen D.E., Yuan J.J.J., Petros J.A., Andriole G.L.: Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med., 324: 1156-1161, 1991.
Chackal-Roy M., Niemeyer C., Moore M., Zeher B.R.: Stimulation of human prostatic carcinoma cell growth by factors present in human bone marrow. J. Clin. Invest., 84: 43-50, 1989.
Clausen H., Hakomori S.: ABH and related histo-blood group antigens: immunochemical differences in carrier isotypes and their distributions. Vox Sang, 56: 1-20, 1989.
Coman D.R., deLong R.P.: The role of the vertebral venous system in the metastasis of cancer to the spinal column. Cancer, 4: 610-618, 1951.
Cooner W.H., Mosley B.R., Rutherford C.L. Jr, Beard J.H., Pond H.S., Terry W.J., Igel T.C., Kidd D.D.: Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination, and prostate specific antigen. J Urol., 143: 1146-1154, 1990.
Cunha G.R., Donjaious A.A., Cooke P.S.: The endocrinology and developmental biology of the prostate. Endocr. Rev., 8:338-362, 1987.
Dennis J.W., Laferté S.: Tumor cell surface carbohydrates and the metastatic phenotype. Cancer Metastasis Rev., 5: 185-204, 1987.
Dennis W., Laferté S., Waghorne C., Breitman M.L., Kerbel R.S.: Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science, 236: 582, 1987.
Dhom G.: Epidemiologic aspects of latent and clinically manifest carcinoma of the prostate. J. Cancer Res. Clin. Oncol., 106: 210, 1983.
Dhom G.: Das Prostatakarzinom und die Bedeutung seiner Früherkennung. Med. Unserer Zeit, 5: 134, 1978.
Dodds P.R., Caride V.J., Lytton B.: The role of the vertebral veins in the dissemination of prostatic carcinoma. J. Urol., 126: 753-755, 1981.
Dong J.T., Lamb P.W., Rinker-Schaeffer C.W., Vukanovic J., Ichikawa T., Isaacs J.T., Barrett J.C.: KAII, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science, 268: 884-886, 1995.
Drickamer K., Carver J. Curr. Opin. Struct. Biol., 2: 653, 1992.
Drury R.A.B., Palmer P.H., Highman W.J.: Carcinomatous metastasis to vertebral bodies. J. Clin. Path., 17: 448-457, 1964.
Egawa S., Shoji K., Go M., Uchida T., Kuwao S., Koshiba K.: Long-term impact of conservative management on localized prostate cancer. Urology, 41: 520, 1993.
Fair W.R.: The natural history of locally confined prostate cancer: a review. The Prostate Supplement, 4: 79-84, 1992.
Filder I.J.: Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res., 50: 6130-6138, 1990.
Foster C.S.: Functional aspects of glycoprotein N-linked oligosaccharide processing by human tumors. Br. J. Cancer, 62: 57-63, 1990.
Foster C.S., McLoughlin J., Bashir I., Abel P.D.: Markers of the metastatic phenotype in prostate cancer. Hum. Pathol., 23(4): 381-394, 1992.
Foster C.S., Neville A.M.: Expression of breast epithelial differentiation antigens in human primary breast cancer. J. Natl. Cancer Inst., 79: 613-622, 1987.
Franks L.M.: Latent carcinoma of the prostate. J. Path. Bact., 68: 603, 1954.
Franks L.M.: The spread of prostatic carcinoma to the bones. J. Pathol. Bact., 66: 91-93, 1953.
Gao X., Zacharek A., Salkowski A., Grignon D.J., Sakr W., Porter A.T., Honn K.V.: Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer. Cancer Res., 55: 1002-1005, 1995.
Gervasi L.A., Mata J.A., Scardino P.T.: The prognostic significance of the extent of nodal metastases in prostatic cancer. J. Urol., 142: 332-336, 1989.
Gibbons R.P., Correa R.J., Brannen G.E., Weissman R.M.: Total prostatectomy for clinically localized prostatic cancer: long term results. J. Urol., 141: 564-566, 1989.
Ginsberg D., De Simone D., Geiger B.: Expression of a novel cadherin (EP-cadherin) in unfertilized eggs and early xenopus embryos. Development, 111: 315-325, 1991.
Grayhack J.T., Grayhack J.J.: Clinical dilemmas and problems in assessing prostatic metastasis to bone: the scientific challenge. In: Prostate cancer and bone metastasis, Karr J.P., Yamanaka H. (Eds.), pp. 1-5, Plenum Press, New York, 1992.
Grayhack J.T., Wendel E.F.: Carcinoma of the prostate, in Practice of rurgery: urology, Karafin L., Kendall A.R. (Eds.), chapter 16, Harper and Row Publishers, Inc., Hagerstown, MD, 1977.
Hadwiger A., Niemann H., Käbisch A., Bauer H., Tamura T.: Appropriate glycosylation of the fms gene product is a prerequisite for its transforming potency. EMBO J., 5: 689-694, 1986.
Hakomori S.-I.: Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv. Cancer Res., 52: 257-61, 1989.
Hakomori S.: Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv. Cancer Res., 52: 257-331, 1989.
Hall J.M., Lee M.K., Newman B., Morrow J.B., Anderson L.A., Huey B., King M.-C.: Linkage of early-onset familial breast cancer to chromosome 17q21. Science (Washington DC), 250: 1684-1689, 1990.
Haq M., Glutzman D., Tremblay G., Brodt P.: Rat prostate adenocarcinoma cells disseminate to bone and adhere preferentially to bone marrow-derived endothelial cells. Cancer Res., 52: 4613-4619, 1992.
Hashimoto M., Niwa O., Nitta Y., Takeichi M., Yokoro K.A.F.: Unstable expression of E-cadherin adhesion molecules in metastatic ovarian tumor cells. Jpn. J. Cancer Res., 80: 459-463, 1989.
Horm J.W., Asire A.J., Young J.L., Pollack A.S.: Cancer incidence and mortality in the United States: 1973-81, NIH Publication No 85-1837, National Cancer Institute, 1984.
Hotta H., Ross A.M., Huebner K., Isobe M., Wendeborn S., Chao M.V., Ricciardi R.P., Tsujimoto Y., Croce C.M., Koprowski H.: Molecular cloning and characterization of an antigen associated with early stages of melanoma tumor progression. Cancer Res., 48: 2955-62, 1988.
Hudson M.A., Bahnson R.R., Catalona W.J.: Clinical use of prostate-specific antigen in patients with prostate cancer. J. Urol., 142: 1011-1017, 1989.
Ichikawa T., Ichikawa Y., Dong J., Hawkins A.L., Griffin C.A., Isaacs W.B., Oshimura M., Barrett J.C., Isaacs J.T.: Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11. Cancer Res., 52: 3486-3490, 1992.
Irimura T., Nakamori S., Matsushita Y., Taniuchi Y., Todoroki N., Tsuji T., Izumi Y., Kawamura Y., Hoff S.D., Cleary K.R., Ota D.M.: Colorectal cancer metastasis determined by carbohydrate-mediated cell adhesion: role of sialyl Lex antigens. Semin. Cancer Biol., 4: 319-324, 1993.
Isaacs J.T.: Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats. Cancer Res., 49: 6290-6294, 1989.
Ishikawa M., Dennis J.W., Man S., Kerbel R.S.: Isolation and characterization of spontaneous wheat germ agglutin-resistant human melanoma mutants displaying remarkably different metastatic profiles in nude mice. Cancer Res., 48: 665-670, 1988.
Jacobs S.C.: Spread of prostatic cancer to bone. Urology, 21: 337-344, 1983.
Johannson J.E., Adami H.O., Andersson S.O., Bergstrom R., Holmberg R., Holmberg L.: High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA, 267: 2191, 1992.
Johnson L.V., Calarco P.C.: Mammalian preimplantation development: the cell surface. Anat. Rec., 196: 201-219, 1981.
Jørgensen T., Berner A., Kaalhus O., Tveter K.J., Danielsen H.E., Bryne M.: Up-regulation of the oligosaccharide sialyl Lewisx: a new prognostic parameter in metastatic prostate cancer. Cancer Res., 55: 1817-1819, 1995.
Klein G.: The approaching era of the tumor suppressor genes. Science, 238: 1539-1545, 1987.
Kondoh M., Ueda M., Ichihashi M., Mishima Y.: Decreased expression of human melanoma-associated antigen ME491 along the progression of melanoma pre-cancerous to invasive and metastatic melanomas. Melanoma Res., 3: 241-5, 1993.
Kozlowski J.M., Grayhack J.T.: Carcinoma of the prostate. In: Adult and pediatric urology, Gillenwater J.Y., Grayhack J.T., Howard S.S., Duckett J.W. (Eds.), pp. 1277-1394, Mosley Year Book, St. Louis, Baltimore, Boston, Chicago, London, Philadelphia, Sydney, Toronto, 1991.
Mansouri A., Spurr N., Goodfellow P.N., Kemler R.: Characterization and chromosomal localization of the gene encoding the human cell adhesion molecule uvomorulin. Differentiation, 38: 67-71, 1988.
Martin-Padura I., Motarini R., Lauri D., Bernasconi S., Sanchez-Madrid F., Parmiani G., Mantovani A., Anichini A., Dejana E.: Heterogeneity in human melanoma cell adhesion to cytokine activated endothelial cells correlates with VLA-4 expression. Cancer Res., 51: 2239-2241, 1991.
Mc Neal J.E.: Origin and development of carcinoma in the prostate. Cancer, 23: 24, 1969.
Metzelaar M.J., Wijngaard P.L., Peters P.J., Sixma J.J., Nieuwenhuis H.K., Clevers H.C.: CD63 antigen. A novel lysosomal membrane glycoprotein, cloned by a screening procedure for intracellular antigens in eukaryotic cells. J. Biol. Chem., 266: 3239-45, 1991.
Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L.M., Ding W., Bell R., Rosenthal J., Hussey C., Tran T., McClure M., Frye C., Hattier T., Phelps R., Haugen-Strano A., Katcher H., Yakumo K., Gholami Z., Schaffer D., Stone S., Bayer S., Wray C., Bogden R., Dayanath P., Ward J., Tonin P., Narod S., Bristow P.K., Norris F.H., Helvering L., Morrison P., Rosteck P., Lai M., Barrett J.C., Lewis C., Neuhausen S., Cannon-Albright L., Goldgar D., Wiseman R., Kamb A., Skolnick M.H.: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science (Washington DC), 266: 66-71, 1994.
Miyake M., Koyama M., Seno M., Ikeyama S.: Identification of the motility-related protein (MRP-1), recognized by monoclonal antibody M31-15, which inhibits cell motility. J. Exp. Med., 174: 1347, 1991.
Murakami Y.S., Brothman A.R., Leach R.J., White R.L.: Suppression of malignant phenotype in a human prostate cancer cell line by fragments of normal chromosomal region 17q. Cancer Res., 55: 3389-3394, 1995.
Muramatsu T.: Carbohydrate signals in metastasis and prognosis of human carcinomas. Glycobiology, 3: 291-296, 1993.
Murphy G.P., Natarajan N., Pontes J.E., Schmitz R.L., Smart C.R., Schmidt J.D., Mettlin C.: The National Survey of prostate cancer in the United States by the American College of Surgeons. J. Urol., 127: 928-934, 1982.
Napolitana E.W., Venstrom K., Wheeler E.F., Reichardt L.F.: Molecular cloning and characterization of B-cadherin, a novel chick cadherin. J. Cell Biol., 113: 893-905, 1991.
Narod S.A., Feunteun J., Lynch H.T., Watson P., Conway T., Lynch J., Lenoir G.M.: Familial breast-ovarian cancer locus on chromosome 17q12-23. Lancet, 338: 82-83, 1991.
Nishijima Y., Uchida K., Koiso K., Nemoto R.: Clinical significance of the vertebral vein in prostate cancer metastasis. In: Prostate cancer and bone metastasis, Karr J.P., Yamanaka H. (Eds.), pp. 93-100, Plenum Press, New York, 1992.
Oesterling J.E., Chan D.W., Epstein J.I., Kimball A.W. Jr, Bruzek D.J., Rock B.C., Brendler C.B., Walsh P.C.: Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J. Urol., 139: 766-772, 1988.
Paulson D.F., Moul J.W., Walther P.J.: Radical prostatectomy for clinical stage T1-2 N0M0 prostatic adenocarcinoma: Long term results. J. Urol., 144: 1180-1184, 1990.
Poste G., Fidler I.J.: The pathogenesis of cancer metastases. Nature, 283:139-146, 1980.
Ranscht B., Bronner-Fraser M.: T-cadherin expression alternates with migrating neural crest cells in the trunk of the avian embryo. Development, 111: 15-22, 1991.
Rinker-Schaeffer C.W., Partin A.W., Isaacs W.B., Coffey D.S., Isaacs J.T.: Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells. The Prostate, 25: 249-265, 1994.
Ross R.K., Paganini-Hill A., Henderson B.E.: The etiology of prostate cancer: What does the epidemiology suggest? The Prostate, 4: 333-344, 1983.
Saithoh O., Wang W.C., Lotan R., Fukuda M.: Differential glycosylation and cell surface expression of lysosomal membrane glycoproteins in sublines of a human colon cancer exhibiting distinct metastatic potentials. J. Biol. Chem., 267: 5700-5711, 1992.
Sandberg A.A.: Cytogenetic and molecular genetic aspects of human prostate cancer: primary and metastatic. In: Prostate cancer and bone metastasis, Karr J.P., Yamanaka H. (Eds.), pp. 45-75, Plenum Press, New York, 1992.
Sandberg A.A.: Chromosomal abnormalities and related events in prostate cancer. Human Pathol., 23 (4): 368-380, 1992.
Sawada R., Tsuboi S., Fukuda M.: Differential E-selectin-dependent adhesion efficiency in sublines of a human colon cancer exhibiting distinct metastatic potentials. J. Biol. Chem., 267: 1425-1431, 1994.
Scardino P.T., Weaver R., Hudson M.A.: Early detection of prostate cancer. Hum. Pathol., 23: 211-222, 1992.
Scott R., Mutchnik D.L., Laskowski T.Z., Schmalhorst W.R.: Carcinoma of the prostate in elderly men: incidence, growth characteristics and clinical significance. J. Urol., 101: 602, 1969.
Shevrin D.H., Kukreja S.C., Ghosh L., Lad T.E.: Development of skeletal metastasis by human prostate cancer in athymic nude mice. Clin. Exp. Metastasis, 6: 401-409, 1988.
Shimoyama Y., Hirohashi S.: Cadherin intercellular adhesion molecule in hepatocellular carcinomas: loss of E-cadherin expression in an undifferentiated carcinoma. Cancer Lett., 57: 459-463, 1989.
Shimoyama Y., Hirohashi S.: Expression of E- and P-cadherin in gastric carcinomas. Cancer Res., 51: 2185-2192, 1991.
Shimoyama Y., Hirohashi S., Hirano S., Noguchi M., Shimosato Y., Takeichi M., Abe O.: Cadherin cell-adhesion molecules in human epithelial tissues and carcinomas. Cancer Res., 49: 2128-2133, 1989.
Silverberg E.S., Boring C.C., Squires T.S.: Cancers statistics. Cancer J. Clin., 40: 9-26, 1990.
Smith J.A., Jr, Haynes T.H., Middleton R.G.: Impact of external irradiation on local symptoms and survival free disease in patients with pelvic lymph node metastasis from adenocarcinoma of the prostate. J. Urol., 131: 705-707, 1984.
Sobel M.E.: Metastasis suppressor genes. J. Natl. Cancer Inst., 82: 267-276, 1990.
Springer T.A.: Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell, 76: 301-314, 1994.
Stamey T.A., Kabalin J.N., McNeal J.E., Johnstone I.M., Freiha F., Redwine E.A., Yang N.: Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J. Urol., 141: 1076-1083, 1989.
Steinberg G.D., Carter B.S., Beaty T.H., Childs B., Walsh P.C.: Family history and the risk of prostate cancer. Prostate, 17: 337-347, 1990.
Suzuki S., Sano K., Tanihara H.: Diversity of the cadherin family: evidence for eight new cadherins in nervous tissue. Cell Regul., 2: 261-270, 1991.
Takeichi M.: Cadherins: a molecular family important in selective cell-cell adhesion. Annu. Rev. Biochim., 59: 237-252, 1990.
Takeichi M.: Cadherin cell adhesion receptors as a morphogenetic regulator. Science, 251: 1451-1455, 1991.
Vallancien G., Prapotnich D., Veillon B., Brisset J.M., Andre-Bougaran J.: Systematic prostatic biopsies in 100 men with no suspicion of cancer on digital rectal examination. J. Urol., 146: 1308-1312, 1991.
Varki A.: Biological roles of oligosaccharide: all the theories are correct. Glycobiology, 3: 97-130, 1993.
Varki A.: Selectin ligands. Proc. Natl. Acad. Sci. USA, 90.
Villers A., McNeal J.E., Redwine E.A., Freiha F.S., Stamey J.: The role of perineural space invasion in the local spread of prostatic carcinoma. J. Urol., 142: 763-768, 1989.
Walsh P.C., Lepor H.: The role of radical prostatectomy in the management of prostatic cancer. Cancer, 60: 526-537, 1987 (suppl).
Ware J.L., Maygarden S.J.: Metastatic diversity in human prostatic carcinoma: implications of growth factors and growth factor receptors for the metastatic phenotype. Pathol. Immunopathol. Res., 8: 231-249, 1989.
Warren L., Buck C.A., Tuszynski G.P.: Glycopeptide changes and malignant transformation. A possible role for carbohydrate in malignant behavior. Biochim. Biophys. Acta, 516: 97-127, 1978.
Zeidman I., Buss J.H.: Transpulmonary passage of tumor cell emboli. Cancer Res., 12: 731-733, 1952.
Zincke H., Utz D.C., Thule P.M., Taylor W.F.: Treatment options for patients with stase D1 (T0-4, N1-2, M0) adenocarcinoma of the prostate. Urology, 30: 307-315, 1987.
